AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37188177
Drug: Patient empowerment
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient empowerment program including educational workshops and videos about mBC and precision medicine
Trial: 37188309
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training (twice a week for 8 weeks, 50 min each session)
Trial: 37188668
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks
Trial: 37188783
Drug: Intratumoral delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 antibody pembrolizumab
Trial: 37188895
Drug: napabucasin (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: napabucasin (480 mg/day) plus sorafenib (800 mg/day)
Trial: 37189075
Drug: First-line pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line pembrolizumab plus chemotherapy in treatment-naïve LCC (n=27)
Trial: 37189075
Drug: First-line pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line pembrolizumab plus chemotherapy in treatment-naïve LCNEC (n=10)
Trial: 37189075
Drug: Subsequent-line pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent-line pembrolizumab with or without chemotherapy in pre-treated LCC (n=23)
Trial: 37189075
Drug: Subsequent-line pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent-line pembrolizumab with or without chemotherapy in pre-treated LCNEC (n=23)
Trial: 37189085
Drug: Normal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal treatment
Trial: 37189171
Drug: Novel medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel medication alerts encouraging collaboration between prescribers and expert pharmacists in anticoagulation clinics.
Trial: 37189171
Drug: Existing prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing prescription notifications for inappropriate DOACs.
Trial: 37189190
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Summer Camp and Parent Intervention (SCV+PI)
Trial: 37190665
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus upper limb robot-assisted therapy (UL-RAT) using an exoskeleton robotic system (Armeo)
Trial: 37190883
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous bone-marrow-derived mononuclear cells with Impella CP device support
Trial: 37190970
Drug: Digital solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital solution (Noona)
Trial: 37190970
Drug: Digital solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital solution
Trial: 37191154
Drug: High-intensity care
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity care (HIC) strategy of guideline-directed medical therapies (GDMT) up-titration
Trial: 37191188
Drug: Arginine methylation
RxNorm normalized name: methyl L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine methylation inhibitors
Trial: 37192040
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 120 mg
Trial: 37192040
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 180 mg
Trial: 37192040
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 240 mg
Trial: 37192282
Drug: Prompted self-measured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompted self-measured blood pressure monitoring and feedback (weekly)
Trial: 37192282
Drug: Prompted self-measured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompted self-measured blood pressure monitoring and feedback (daily)
Trial: 37192288
Drug: Cardiac scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac scale measurements (daily)
Trial: 37192754
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion to increase mean arterial blood pressure (MAP) by a maximum of 30 mmHg to an absolute level of no more than 130 mmHg.
Trial: 37192754
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion to increase MAP.
Trial: 37194068
Drug: Individualized dosing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dosing of follitropin delta (average daily dose 11.0 ± 1.6 µg, duration 10.3 ± 1.6 days)
Trial: 37194068
Drug: Individualized dosing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dosing of follitropin delta
Trial: 37194074
Drug: Group well
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group well child care provided on-site at a maternal substance use disorder treatment program.
Trial: 37194394
Drug: Brepocitinib 30
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brepocitinib 30 mg once daily
Trial: 37194394
Drug: Brepocitinib 60
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brepocitinib 60 mg once daily
Trial: 37194394
Drug: Brepocitinib 30
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brepocitinib 30 mg and 60 mg once daily
Trial: 37194458
Drug: Preoperative hyper-polypharmacy
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hyper-polypharmacy (greater than or equal to 10 medications)
Trial: 37194458
Drug: Preoperative polypharmacy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative polypharmacy (5-9 medications)
Trial: 37194458
Drug: Non-polypharmacy (fewer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-polypharmacy (fewer than 5 medications)
Trial: 37194488
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) 1.5 mg/kg intravenous infusion, administered 15 minutes prior to surgery
Trial: 37194813
Drug: Medium intensity
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium intensity coughing technique during subcutaneous low molecular weight heparin injection
Trial: 37195023
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ONC201 and paxalisib
Trial: 37195128
Drug: ICI combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI combined with chemotherapy
Trial: 37195423
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) monotherapy after ultra-short-pulse glucocorticoids (GCs)
Trial: 37195666
Drug: Deliberate practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deliberate practice intervention (3 weekly, 30-minute video-conferenced sessions with personalized feedback)
Trial: 37195667
Drug: SIB-RT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIB-RT with concurrent and consolidated oral S-1 chemotherapy (CRTCT group)
Trial: 37195941
Drug: 700 mg
RxNorm normalized name: cystine 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg of peresolimab
Trial: 37196061
Drug: PXVX0317 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXVX0317 vaccine
Trial: 37196069
Drug: Hypofractionated stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated stereotactic radiotherapy (hFSRT) combined with 1500 mg Durvalumab on day 5, followed by infusions every 4 weeks for up to 12 months.
Trial: 37196396
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) treatment for OSAS
Trial: 37196527
Drug: Metarrestin (ML-246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metarrestin (ML-246) administered orally at a dose of 1 mg
Trial: 37197905
Drug: Test, treat,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test, treat, retest and re-treat initial treatment failures
Trial: 39666396
Drug: NVX-CoV2373 booster
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 booster dose
Trial: 37199326
Drug: Pembrolizumab combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab combined with quad-shot radiotherapy (14.8 Gy in four twice-daily fractions)
Trial: 37199427
Drug: Maternal tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maternal tenofovir disoproxil fumarate-based antiretroviral treatment (mART)
Trial: 37199438
Drug: Hip Fracture
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip Fracture Injection (HiFI) - multimodal local injection of bupivacaine, morphine sulfate, ketorolac at the fracture site during surgery
Trial: 37199438
Drug: Hip Fracture
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip Fracture Injection (HiFI)
Trial: 37199745
Drug: Fenretinide (4-HPR)
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide (4-HPR) 600 mg/m
Trial: 37199745
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fenretinide plus safingol
Trial: 37199884
Drug: Upadacitinib (UPA)
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib (UPA) 6 mg BID, titrated to 12 mg BID if necessary, later replaced by 15/30 mg once-daily extended-release equivalents
Trial: 37200944
Drug: High energy-dense
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy-dense oral nutritional supplement (edONS, 2.4 kcal/mL)
Trial: 37200944
Drug: Reference oral
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference oral nutritional supplement (heONS, 2.0 kcal/mL)
Trial: 37201438
Drug: Remotely delivered,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotely delivered, individualized, and self-directed gait modification with weekly telerehabilitation appointments and remote monitoring
Trial: 37201546
Drug: Immediate Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Sequential Bilateral Cataract Surgery (ISBCS)
Trial: 37201546
Drug: Delayed Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Sequential Bilateral Cataract Surgery (DSBCS)
Trial: 37201747
Drug: M-TAPA (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-TAPA (40 ml 0.25% bupivacaine)
Trial: 37201756
Drug: Preoperative Proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative Proton Beam Therapy with Concurrent Chemotherapy
Trial: 37201900
Drug: Ketamine intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine intravenous therapy (KIT) induction
Trial: 37201900
Drug: Ketamine intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine intravenous therapy (KIT) maintenance
Trial: 37201900
Drug: Ketamine intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine intravenous therapy (KIT) at eight weeks
Trial: 37202039
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy received in the first days of intensive care admission
Trial: 37202042
Drug: ω-3 fatty
RxNorm normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 fatty acid ethyl esters (4 g/day)
Trial: 37202073
Drug: Semi-elemental enteral
RxNorm normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-elemental enteral formula with partially hydrolyzed guar gum (PHGG) at 12 g/L
Trial: 37202530
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega 3 supplement (40 mg/kg/day) for 2 weeks
Trial: 37202813
Drug: Dapagliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (5 mg p.o./day for 2 weeks escalated to 10 mg p.o./day for 6 weeks)
Trial: 37202822
Drug: TAPER (team
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAPER (team approach to polypharmacy evaluation and reduction)
Trial: 37203207
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of gas in fistula and clinical finding of fluid discharge through the external fistula opening at 3 months
Trial: 37204106
Drug: INO-3107 administered
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INO-3107 administered by intramuscular injection followed by electroporation on weeks 0, 3, 6, and 9.
Trial: 37205012
Drug: Direct-to-implant (DTI)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-to-implant (DTI)
Trial: 37205592
Drug: Bivalent and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters (Moderna mRNA-1273, Pfizer-BioNTech BNT162b2, Sanofi CoV2 preS DTM-AS03)
Trial: 37205592
Drug: Prototype/Wildtype Vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype/Wildtype Vaccines
Trial: 37205721
Drug: IDA1 (ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDA1 (ivermectin 150 μg/kg + albendazole 400 mg + diethylcarbamazine 6 mg/kg)
Trial: 37205721
Drug: IDA3 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDA3 (three consecutive daily doses of IDA)
Trial: 37205721
Drug: IA (ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA (ivermectin 150 μg/kg + albendazole 400 mg)
Trial: 37205721
Drug: IDA treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDA treatments (both IDA1 and IDA3 combined)
Trial: 37206279
Drug: GS-0189 as
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-0189 as monotherapy and in combination with rituximab
Trial: 37206996
Drug: CT-STAR (cone-beam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-STAR (cone-beam computed tomography-guided stereotactic adaptive radiation therapy)
Trial: 37207143
Drug: Vanucizumab in
RxNorm normalized name: Vanucizumab
DrugBank: Vanucizumab (DB12317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanucizumab in combination with mFOLFOX-6 chemotherapy
Trial: 37207143
Drug: Bevacizumab (VEGF-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (VEGF-A inhibitor) in combination with mFOLFOX-6 chemotherapy
Trial: 37207300
Drug: Switched endocrine
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched endocrine therapy (fulvestrant or exemestane) plus ribociclib
Trial: 37207300
Drug: Switched endocrine
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched endocrine therapy (fulvestrant or exemestane) plus placebo
Trial: 37207382
Drug: Eteplirsen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eteplirsen (30 mg/kg, once-weekly intravenously for 10 weeks, continuing at 30 mg/kg up to 96 weeks)
Trial: 37207382
Drug: Eteplirsen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eteplirsen (30 mg/kg)
Trial: 37207654
Drug: tislelizumab-chemotherapy
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tislelizumab-chemotherapy
Trial: 38607538
Drug: placebo-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo-chemotherapy
Trial: 37207655
Drug: PI3K inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PI3K inhibitors (specifically alpelisib)
Trial: 37207810
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure for 6 weeks
Trial: 37208132
Drug: Projection-based augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Projection-based augmented reality exposure treatment system (P-ARET)
Trial: 37208132
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo exposure treatment (IVET)
Trial: 37208133
Drug: MK-7 (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7 (333 µg/day)
Trial: 37208142
Drug: Projection-based AR
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Projection-based AR exposure therapy with multiple stimuli (P-ARET MS)
Trial: 37208142
Drug: Projection-based AR
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Projection-based AR exposure therapy with a single stimulus (P-ARET SS)
Trial: 37208431
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose 7.5 mg/kg
Trial: 37208431
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose 15 mg/kg
Trial: 37208556
Drug: Ponatinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib + steroids
Trial: 37208556
Drug: Imatinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib monotherapy induction + imatinib-containing consolidation
Trial: 37208675
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 2% lidocaine with epinephrine 1:200,000
Trial: 37208675
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 2% lidocaine with epinephrine 1:200,000 plus 2 mL sodium bicarbonate 4.2% (total of 12 mL)
Trial: 37209152
Drug: 50 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU/kg unfractionated heparin (UFH)
Trial: 37209152
Drug: 100 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU/kg unfractionated heparin (UFH)
Trial: 37209152
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg enoxaparin
Trial: 37209152
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg enoxaparin
Trial: 37209238
Drug: Interferon/ribavirin (prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon/ribavirin (prior treatment)
Trial: 37209243
Drug: Intraosseous computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous computerized anaesthesia (ICA) with 1.8 mL of 4% articaine with 1:100 000 epinephrine
Trial: 37209243
Drug: Conventional inferior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional inferior alveolar nerve block (IANB) with 1.8 mL of 4% articaine with 1:100 000 epinephrine
Trial: 37209422
Drug: Technology-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-based training in exposure therapy
Trial: 37209421
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment support via free combination NRT at discharge and automated counseling
Trial: 37209421
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment support
Trial: 37209427
Drug: Ulotaront 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulotaront 25 mg
Trial: 37209427
Drug: Ulotaront 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulotaront 50 mg
Trial: 37209700
Drug: AAd5 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAd5 (0.1 mL)
Trial: 37209700
Drug: IMAd5 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMAd5 (0.3 mL)
Trial: 37209700
Drug: Inactivated vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated vaccine (BBIBP-CorV or CoronaVac; 0.5 mL)
Trial: 37209893
Drug: Intrauterine balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine balloon tamponade combined with sulprostone infusion